NCT04840589 2026-03-18
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
National Cancer Institute (NCI)
Phase 1 Suspended
Clinical Trials
12 trialsNCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT06666218 2026-01-14
Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)
Fred Hutchinson Cancer Center
Phase NA Suspended
NCT05866679 2025-10-14
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
M.D. Anderson Cancer Center
Phase 1 Suspended
NCT03275298 2025-04-23
ESME OC
UNICANCER
Suspended
NCT04711161 2024-01-23
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Green3Bio, Inc.
Phase 1 Suspended
NCT05506800 2023-02-23
Guangzhou Women's Health Cohort Study (GWHCS)
Guangzhou Women and Children's Medical Center
Suspended
NCT04042116 2022-12-20
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
Phase 1/2 Suspended
NCT01218490 2019-05-16
CARACO
Institut Cancerologie de l'Ouest
Phase 3 Suspended
NCT03393962 2018-07-31
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Suspended
NCT02093871 2017-07-21
PISH-2
ThermalCore Inc
Phase 1 Suspended
NCT00753480 2008-11-07
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
Phase 1 Suspended